ATP-dependent D-alanine:D-alanine ligase (Ddl) is a part of biochemical machinery involved in peptidoglycan biosynthesis, as it catalyzes the formation of the terminal D-ala-D-ala dipeptide of the peptidoglycan precursor UDPMurNAc-pentapeptide. Inhibition of Ddl prevents bacterial growth, which makes this enzyme an attractive and viable target in the urgent search of novel effective antimicrobial drugs. To address the problem of a relentless increase in resistance to known antimicrobial agents we focused our attention to discovery of novel ATP-competitive inhibitors of Ddl.
Encouraged by recent successful attempts to find selective ATP-competitive inhibitors of bacterial enzymes we designed, synthesized and evaluated a library of 6-arylpyrido[2,3-d]pyrimidine-based compounds as inhibitors of Escherichia coli DdlB. Inhibitor binding to the target enzyme was subsequently confirmed by surface plasmon resonance and studied with isothermal titration calorimetry. Since kinetic analysis indicated that 6-arylpyrido[2,3-d]pyrimidines compete with the enzyme substrate ATP, inhibitor binding to the ATP-binding site was additionally studied with docking. Some of these inhibitors were found to possess antibacterial activity against membrane-compromised and efflux pump-deficient strains of E. coli.
Citation: Škedelj V, Arsovska E, Tomašić T, Kroflič A, Hodnik V, Hrast M, et al. (2012) 6-Arylpyrido[2,3-d]pyrimidines as Novel ATP-Competitive Inhibitors of Bacterial D-Alanine:D-Alanine Ligase. PLoS ONE 7(8): e39922. https://doi.org/10.1371/journal.pone.0039922
Editor: Eric Cascales, Centre National de la Recherche Scientifique, France
Received: April 6, 2012; Accepted: May 29, 2012; Published: August 2, 2012
Copyright: © Zega et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Slovenian Research Agency (Grant P1-0208). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
The worldwide emergence over the past three decades of bacterial strains resistant to most current antibiotics constitutes a serious threat to global public health and has led to considerable efforts to identify and exploit new antibacterial targets and novel antimicrobial agents , . Bacterial cell wall peptidoglycan synthesis has proven to be a well-established and validated target for antibacterial action, since it is the site of action of the clinically important ß-lactam and glycopeptide classes of antibiotics . The disaccharide-pentapeptide peptidoglycan structure is a specific and essential component of the bacterial cell wall whose main function is to preserve cell integrity by resisting high internal osmotic pressure and maintain a defined cell shape . It is a common feature of both Gram-negative and Gram-positive bacteria and is therefore an attractive target for the development of broad-spectrum antibacterials . The biosynthesis of peptidoglycan can be divided into 3 sequential stages, each comprising a series of reactions occurring at different locations in bacteria: in the cytoplasm (synthesis of the nucleotide precursors), on the inner side (synthesis of lipid-linked intermediates) and outer side (polymerization reactions) of the cytoplasmic membrane , . Of the enzymes that act in the first stage, D-alanine:D-alanine ligase (Ddl) is of particular interest, as it utilizes a substrate (D-alanine), which is specific for bacterial peptidoglycan biosynthesis, and is essential for bacterial growth , . Ddl catalyzes the ATP-dependent formation of a dipeptide D-Ala-D-Ala that subsequently occupies the terminal position of the cell wall UDP-MurNAc-pentapeptide precursor units. This terminal dipeptide plays a pivotal role in the extracellular steps of peptidoglycan assembly, where cross-linking of adjacent peptidoglycan chains occurs via breaking a dipeptide bond and forming a new one .
D-Alanine:D-alanine ligase (EC 184.108.40.206) was first detected in the early 1960s and soon afterwards partially purified from Enterococcus faecalis. Kinetic and specificity studies of the reaction were performed on the purified ligase and provided evidence for two D-Ala binding sites with different substrate affinities , . Ddl enzymes from various Gram-negative and Gram-positive pathogens have been isolated and characterized since then, including D-alanine:D-alanine ligase from Escherichia coli, in which two isoforms of the enzyme exist, DdlA and DdlB, that exhibit 35% amino acid sequence identity. They also express similar kinetic characteristics, substrate specifity and sensitivity for known inhibitors, but since DdlB is more extensively studied, we focused our attention on this isoform., .
DdlB consists of three α+ß domains with an unusual nucleotide-binding fold, referred to as the ATP-grasp fold . The overall chemical transformation catalyzed by the ATP-grasp fold proteins is the formation of a carbon-nitrogen bond; they have, therefore, been referred to as carboxylate-amine ligases. Members of this superfamily have a common three domain molecular architecture with the nucleotide triphosphate-binding pocket positioned at the interface between the N- and C-terminal domains (Figure 1). They also have a common reaction mechanism that requires Mg2+ and ATP for the formation of an acylphosphate intermediate . In the initial step of Ddl catalyzed reaction, ATP is bound to the free enzyme, followed by D-Ala1. Subsequent phosphorylation of the amino acid carboxylate by the γ-phosphate of ATP generates an acyl phosphate intermediate which is attacked by the amino group of the D-Ala2 to yield the dipeptide D-Ala-D-Ala (Figure 2) , , .
Since the first report of Ddl 50 years ago, four main categories of inhibitors of this enzyme have been described: analogues of D-Ala, analogues of product, transition state analogues and, more recently, inhibitors discovered by either screening or modeling . The first discovered, and also the most important, inhibitor of Ddl is D-4-amino-3-isoxazolidone (D-cycloserine), a structural analogue of the natural substrate D-alanine with a Ki of 27 µM . D-cycloserine is the only Ddl inhibitor that has been used in the clinic, mainly in combination with other antibiotics for the treatment of tuberculosis, but, due to its high minimal inhibitory concentration (MIC) values and neurological side effects, its use has been almost completely abandoned . Since Ddl is strongly inhibited by its reaction product D-Ala-D-Ala, a wide variety of mixed dipeptide analogues have been tested for inhibition of the enzyme and several have proved to be slightly more effective inhibitors than the natural reaction product . Phosphinate and phosphonate dipeptides have been described as transition-state mimetics but, despite their potent activity against isolated enzymes, they failed to show significant antibacterial activity, probably related to poor transport into bacteria . Over the last few years several new inhibitor scaffolds that show no structural similarity with the substrate, product or reaction intermediate have been identified by de novo structure-based drug design ,  and by virtual screening , , , , .
The lack of potent Ddl inhibitors complying with the requirements for routine use in antibacterial therapy inspired us to search for new inhibitor scaffolds for the target enzyme. Up to now most attention has been focused on substrate, product or transition-state analogues, leaving the ATP-binding site quite unexploited. Only few of existing Ddl inhibitors interfere with the binding of ATP to the target enzyme. Two flavonoids, apigenin and quercetin have proven to be potent ATP-competitive inhibitors of DdlB and Helicobacter pylori Ddl with antibacterial activity, but since they also act on other targets in bacteria (DNA gyrase, membrane, fatty acid biosynthesis), it is difficult to attribute their activity to the inhibition of cell wall synthesis only . A common topology of the ATP-binding site of Ddl and different classes of kinases resulted in evaluation of a series of ATP competitive kinase inhibitors and identifying a few potent ATP-competitive inhibitors of E. coli DdlB . Finally, two new and structurally diverse ATP-competitive inhibitors of DdlB from NCI database with IC50 values in the low micromolar concentration range were evidenced using structure-based virtual screening , .
Targeting the ATP-binding site of bacterial enzymes is associated with several problems. An ATP-competitive inhibitor of bacterial enzyme must be able to compete with the high ATP concentration in the bacterial cell (0.6–18 mM), which is similar to that in human cells (1–10 mM). Additionally, inhibitor binding to the ATP-binding site must be selective for the target bacterial enzyme over human ATP-dependent enzymes, particularly kinases. However, recent successful examples of ATP-competitive bacterial enzyme inhibitors possessing antibacterial activity and displaying good selectivity profiles with respect to human enzymes show that these challenges can be overcome .
Ddl belongs to the ATP-grasp superfamily which currently includes 21 groups of enzymes. We studied the ATP-binding site of DdlB ligase (PDB entry: 1IOW) using ProBiS, a Web server for detecting protein binding sites based on local structural alignments, and found that the Ddl ATP-binding site is structurally similar to the those of 80 enzymes in the RCSB Protein Data Bank. Top ranked structures belong to other bacterial members of the ATP-grasp superfamily, such as Ddl from other bacterial strains, D-alanine:D-lactate ligase, carbamoyl phosphate synthetase, biotin carboxylase (BC), acetyl-CoA carboxylase and glutathione synthetase, and show less similarity to ATP-utilizing human enzymes, since only 7 ranked enzyme structures are of human origin (Table S1). Although this study included only enzymes with known crystal structure, we may assume that ATP-binding site of Ddl ligase represents a promising target for the design of ATP-competitive ligands that do not interact with human ATP-binding enzymes.
Recently, Miller et al. identified promising hits targeting the ATP-binding site of biotin carboxylase (BC) from the Pfizer series of pyridopyrimidines that emerged from a structure-based drug design program targeting eukaryotic protein kinases . Based on these encouraging results and structural similarity between DdlB and BC, we developed and evaluated a library of 6-arylpyrido[2,3-d]pyrimidines as inhibitors of DdlB that inhibit the target enzyme with IC50 values in the micromolar range. Inhibitor binding was subsequently confirmed with surface plasmon resonance (SPR) and studied by isothermal titration calorimetry (ITC). Docking was performed to clarify the binding mode of the inhibitor to the DdlB ATP-binding site.
Results and Discussion
The starting point for our attempt to discover novel DdlB inhibitors was the previously described ATP-competitive BC inhibitor 33 (Figure 3), given the structural similarity between DdlB and BC ATP-binding sites. It exhibits an IC50 less than 5 nM for the E. coli BC enzyme, antibacterial activity in vitro and in vivo and a high resolution X-ray crystal structure of BC-33 complex has been determined .
We postulated that the pyridopyrimidine moiety could interact with the adenine-binding region in the ATP-binding site of our target enzyme and, since this core structure allows the introduction of different substituents onto three regions of the molecule, it offers a good opportunity to create additional interactions in the active site. In the first phase, we examined whether the selected scaffold shows any inhibition of DdlB. We prepared compound 33 and a series of additional nine 2,7-unsubstituted diamines (11, 13, 18, 20, 22, 24, 26, 31 and 35) from commercially available or easily synthesized acetonitriles, and tested them for inhibition of the target enzyme (Figures 4, 5, 6, 7). Encouraged by the promising DdlB inhibitory activity of compound 33 and analogues, we assessed the role of N-2 and N-7 substitution on the inhibitory activity of target compounds. Corresponding N-7 tert-butylurea derivatives (12, 14, 19, 21, 23, 25, 27, 32, 34 and 36) were synthesized initially. The 3,5-dimethoxyphenyl- and 2,6-dichlorophenyl- [2,3-d]pyridopyrimidine derivatives were selected for further optimization due to the synthetic accessibility of corresponding acetonitriles and few compounds were designed and synthesized to explore the impact of N-2 substitution alone (15, 17, 28 and 30) and together with the reintroduction of tert-butyl urea on N-7 (16 and 29). Since the series of previously prepared compounds exhibited poor solubility, we introduced a basic aliphatic side chain at N-2 to improve aqueous solubility. Two aliphatic amines were selected, namely the 3-(dimethylamino)propylamine and the more bulky 4-(3-aminopropyl)morpholine, for exploration of the space around the distal amine.
The syntheses of compounds reported in this paper are outlined in Figure 8 and described in details in Information S1. In the first step, 2,4-diamino-5-cyanopyrimidine (1) was prepared according to the method reported by Huber , by condensing guanidine nitrate with ethoxymethylenemalononitrile in ethanol in the presence of a significant amount of sodium ethoxide, to form the free guanidine base. The cyano group was reduced using Raney nickel as catalyst and 98% formic acid as solvent .
h (b) Ra-Ni, 98–100% HCOOH (c) NaH, EtO(CH2)2OH, reflux, 4 h. (d) NaH, R2NCO/R2NCS, DMF, room temp, 18 h. (e) R3NH2, NH2SO3H, reflux, 42–72 h. (f) NaH, R2NCO/R2NCS, DMF, room temp, 18 h.
The resulting 2,4-diaminopyrimidine-5-carboxaldehyde (2) was condensed with commercially available or synthesized benzylnitriles (7–10) under basic conditions to give 2,7-diaminopyridopyrimidines (11, 13, 18, 20, 22, 24, 26, 31, 33 and 35) that were then treated further in two different ways. In the first stage, the diamine was acylated only at N-7, using 1 equivalent of basic NaH and 1 equivalent of isocyanate to give the final monosubstituted compound (12, 14, 19, 21, 23, 25, 27, 32, 34 and 36) with traces of bis-2,7-urea by-product . Alternatively, the N-2 amine of the diamine was first substituted selectively in the presence of an acid such as sulfamic acid, with a refluxing nucleophilic aminoalkylamine as solvent (15, 17, 28 and 30). The latter was finally treated with 1 equivalent of NaH, followed by acylation with 1 equivalent of an acylating agent tert-butyl isocyanate to give the target urea compound (16 and 29).
The preparation of commercially unavailable phenylacetonitriles was achieved using two different approaches (Figure 9). In the first, the target compound was obtained from commercially available benzaldehydes in three steps. Reduction with sodium borohydride afforded the corresponding alcohol (3)  which was then converted to the respective bromide (4) by treatment with carbon tetrabromide and triphenylphosphine in THF , with subsequent cyanide displacement with KCN in a boiling mixture of ethanol and water. The initial step in the second approach was benzylic bromination of substituted toluene using N-bromosuccinimide in CCl4 to yield the bromide 6, which was then converted to the corresponding cyanide 8 in the presence of KCN, as described previously .
All of the synthesized 6-arylpyrido[2,3-d]pyrimidines 11–36 were assayed for in vitro inhibitory activity on E. coli DdlB by detecting orthophosphate generated during the enzymatic reaction using a Malachite green assay . The results are presented as residual activities (RAs) of the enzyme in the presence of 100 or 250 μM of target compounds and as IC50 values for the most active compounds (Figures 4, 5, 6, 7). As a positive control in our assay we used D-cycloserine that exhibited IC50 value of 296 μM.
Three regions of the basic scaffold were targets for structure-activity relationship studies. Analogues with modifications of the 2-, 6-, and 7-positions were synthesized and evaluated for their inhibition of DdlB. The effects of phenyl substitution were investigated first. Compound 11 possessing an unsubstituted phenyl ring showed weak inhibition of the target enzyme, with an IC50 of 1140 µM. Disubstituting the meta positions of the phenyl ring did not lead to significant improvement of inhibitory potency (13, 18, 20 and 22), while, in contrary, disubstitution at the ortho positions resulted in the most potent inhibitor in the series of 6-arylpyrido[2,3-d]pyrimidine-2,7-diamines, with bromine introduced into the phenyl ring (33), which inhibited DdlB with an IC50 value of 453 μM. Incorporation of the fluorine in the phenyl ring did not have any impact on the inhibitory activity in the series of unsubstituted diamines (20 and 24) as well as in the next designed series (21 and 25) of 6-arylpyrido[2,3-d]pyrimidines, in which we examined the attributes of tert-butylurea substitution at the N-7 position. The inhibitory potency was significantly increased in the compounds with meta disubstitution at phenyl moiety in the 6-position. The 3′,5′-dimethoxy-substituted tert-butylurea derivative 14 with an IC50 value of 340 μM displays a 2.6-fold greater inhibitory potency as its corresponding diamine 13 and a similar trend can be seen for 3,5-bis(trifluoromethyl)- (compound 19, IC50, 260 μM) and3′,5′-dichloro- tert-butylurea derivative 23 (IC50, 383 μM). On the other hand, if the tert-butylurea moiety was introduced at the N-7 position ofortho substituted 6-arylpyrido[2,3-d]pyrimidines, inhibition of the target enzyme was slightly reduced (26 vs. 27, 33 vs 34).
The effect of N-2 substitution of the 2,7-diamino series of compounds on DdlB inhibition was investigated by incorporating basic aliphatic side chains at N-2 of the pyridopyrimidine scaffold. The introduction of a 3-(dimethylamino)propyl moiety reduced the DdlB inhibitory activity (17 and 30). An N-morpholinopropyl moiety, which was used for examination of steric constraints around the distal amine, had the same effect (15 and 28). However, reintroduction of tert-butylurea on the N-7 amine resulted in the most potent DdlB inhibitor in our studies, compound 16, with an IC50 value of 133 μM.
Additionally we performed detailed inhibition studies for two selected compounds, namely the most potent inhibitor from 6-arylpyrido[2,3-d]pyrimidine-2,7-diamines, compound 33, and compound 14, which belongs to the series of tert-butylureas. Inhibition of DdlB was measured at different inhibitor and ATP concentrations in order to determine Ki values and the mode-of-action of both compounds. Kinetic analysis, as expected, revealed inhibition of the enzyme in an ATP-competitive mode for both compounds, 14 and 33, with Ki values of 31±4 μM and 38±5 μM, respectively (Figure S1).
Surface Plasmon resonance
The binding of the compounds 11, 13, 14, 24, 27, 33, and 35 to the target enzyme was confirmed using surface plasmon resonance (SPR) (Figure 10). Experiments were performed at conditions that enable long term stability of the enzyme. We found that in the buffer 50 mM Hepes, 150 mM NaCl, 5% DMSO, pH 8.0 the enzyme was stable for several days so that we could analyzed the binding of many compounds. The enzyme was covalently attached to the surface of a sensor chip CM5 and compounds were titrated over the surface. The binding of all the compounds was characterised by fast association and dissociation rates. Equilibrium affinity constants, estimated from the steady-state binding levels are in agreement with enzymatic studies and ITC. In addition, the binding of other compounds was tested but insufficient solubility at higher concentrations of analytes in the running buffer precluded analysis.
Different concentrations of compounds were tested for the binding (left panels in all cases). The binding curves (right panels) were generated by ploting steady-state response levels, i.e. at the end of the association phase, vs concentration of the injected compound. The KDs were obtained from fitting the data to the steady-state affinity model and are reported in Table 1. For each compound 3–5 independent titrations were performed.
Isothermal titration calorimetry
Two of the compounds, 14 and 33, were also tested by ITC to obtain thermodynamic parameters of the binding into DdlB active site. Heat changes upon binding of the ligand on the E. coli DdlB were measured directly, corrected for the heats of dilution, and the model function was fitted to the experimental data points (see the Experimental section).
The value of critical parameter for obtaining highly reliable thermodynamic data () was not optimal due to low inhibitors solubility and quite low binding constants. Nevertheless, the conclusions below can be drawn. Experiments for the two compounds result in similar binding constants (Kb≈105 M−1) (Table 1), but the driving forces for the binding differ (Figure 11). The binding of compound 14 to DdlB results from favourable enthalpy and entropy contributions. In contrast, the binding of compound 33 is entropy driven, what is characteristic of a hydrophobic interaction (positive entropy change accompanying the release of ordered water molecules at the nonpolar surfaces in the bulk), and accompanied by positive enthalpy change. But still, compensation of the opposing effects at 33 results in similar (and binding constant) as at 14, although there are less specific interactions between 33 and the protein as at 14. In other words, ITC experiments reveal comparable binding affinity of the tested compounds to DdlB active site; however more hydrogen bonds are formed upon binding of 14 obviously, what is also supported with the docking results.
Plausible binding modes of the target compounds in the active site of E. coli DdlB were explored by docking the ligands using CDOCKER algorithm, as available in Accelrys Discovery Studio 3.0. The binding site was defined as a sphere with radius 13.9 Å around the centroid of the ADP molecule in the crystal structure of DdlB-ADP-phosphoryl phosphonate inhibitor ternary complex (PDB entry: 1IOV ). The defined binding site was large enough to include the ATP- and both D-Ala-binding sites of the DdlB active site. Prior to docking the potential DdlB inhibitors, CDOCKER docking protocol was validated by redocking ADP in the defined binding site. The program reproduced the experimentally determined binding mode of ADP with an all heavy atom RMSD of only 0.58 Å, which confirmed its suitability for prediction of binding modes of the designed DdlB ligands.
Docking of inhibitors 14 and 33 in the E. coli DdlB active site (Figure 12) predicted their binding in the ATP-binding site, while both D-Ala-binding sites remained unoccupied. The pyrido[2,3-d]pyrimidine ring of 33 is predicted to bind in the adenine-binding pocket of the DdlB active site. Similar binding of the pyrido[2,3-d]pyrimidine ring has already been observed in the crystal structure of biotin carboxylase in complex with 33 (PDB entry 2V58).. However, the binding mode of 33 in the biotin carboxylase active site differs from its predicted binding mode in the DdlB active site (Figure 12 and Figure S2). Compound 33 forms five hydrogen bonds with amino acid residues and additional hydrophobic interaction in the biotin carboxylase ATP-binding site (Figure S2), which results in the very potent inhibitory activity (IC50 less than 5 nM). In contrast, inhibitor 33 forms, according to the docking prediction, only one hydrogen bond with the side chain amino group of Lys144 and hydrophobic interactions with Ile142 and Met154 in the DdlB ATP-binding site, and inhibits the enzyme with an IC50 of 453 µM. Similarly, the pyrido[2,3-d]pyrimidine ring of 14 is seen to occupy the adenine-binding pocket of DdlB active site, but in an orientation different from that in the case of 33 (Figures 12a and 12c). A hydrogen bond is formed between the inhibitor amino group at position 2 and the carbonyl oxygen of Lys181. Additional hydrogen bonds are formed between the inhibitor urea NH groups and the Glu187 side chain carboxylate group, and between the inhibitor methoxy group and the Ser151 side chain hydroxyl group. Inhibitor 14 also forms additional hydrophobic contacts within the DdlB ATP-binding site. These docking results are in a good agreement with the results obtained by ITC, which showed mainly hydrophobic interaction as the driving force in binding 33 and favourable enthalpy and entropy contributions to the binding of 14.
Selected DdlB inhibitors were tested for their antibacterial activity against two E. coli strains E. coli 1411 and E. coli AB734 (Table 2). Compounds 14, 22, 27 and 35 were inactive against all strains with MICs >256 μg/mL. Only 6-arylpyrido[2,3-d]pyrimidines with unsubstituted amino groups and disubstitution at the ortho position of the phenyl ring (compounds 24, 26 and 33) were found to inhibit both these strains, with MICs of 64 μg/mL and 32 μg/mL, respectively. Additionally, growth inhibition of efflux pump-deficient strains SM1411 (acrAB deficient derivative of 1411)  and ES100 (tolC deficient derivative of AB734)  was measured, and MICs were repeated for each strain in the presence of polymyxin B nonapeptide (PMBN) to assess the impact of outer-membrane permeability on antimicrobial activity . Compounds 24, 26 and 33 showed improvedMIC valuesagainst efflux-deficient, permeabilised cells, and compounds 16, 19, 23 and 34 (which are mono- or disubstituted 6-arylpyrido[2,3-d]pyrimidines) also showed weak antibacterial activity.
The lack of correlation between enzyme inhibitor activity and antibacterial activity (Figures 4, 5, 6, 7 and Table 2) suggests that the antibacterial activities observed for the starting point compound 33 and the analogues 24 and 26 may primarily be due to inhibition of another bacterial target, and not DdlB.
To conclude, we have designed, synthesized and evaluated a series of novel inhibitors of E. coli DdlB based on the 6-arylpyrido[2,3-d]pyrimidine scaffold. Best activity was achieved by disubstituted 6-arylpyrido[2,3-d]pyrimidine 16 (IC50 value of 133 μM) which demonstrated 3.4-fold improved IC50 value against DdlB compared to the lead compound 33. For 7 selected compounds positive results from enzyme assays were additionally confirmed by surface plasmon resonance experiments, which show fast and tight binding of examined inhibitors to the DdlB. The mode-of-action was studied in detail for compounds 14 (IC50 value of 340 μM) and 33 (IC50 value of 453 μM) with a steady-state kinetic study, which revealed that both compounds, 14 and 33, act as ATP competitive inhibitors of DdlB with Ki values of 31±4 μM and 38±5 μM, respectively. ITC data for the compounds 14 and 33 showed that the thermodynamic binding profile of compound 14 to DdlB elicited a favourable enthalpy and entropy contributions in comparison with the binding of compound 33, which is entropy driven. Docking results are also in a good agreement with the results obtained by ITC. Some of the inhibitors exhibit antibacterial activity against E.coli, although their activity against wild-type strains is limited by outer membrane impermeability and efflux. It remains to be established whether the antibacterial effect results specifically from inhibition of DdlB in whole bacterial cells. The compounds in this study may serve as starting points for the development of bi-substrate inhibitors that incorporate both, an ATP-competitive and D-alanine competitive moieties, which would exhibit enhanced selectivity and potency profiles by preferentially inhibiting Ddl over kinases.
Materials and Methods
Chemicals were obtained from Acros, Aldrich Chemical Co., Apollo Scientific, and Fluka and used without further purification. Analytical thin-layer chromatography was performed on silica gel Merck 60 F254 precoated plates (0.25 mm), visualized with ultraviolet light, ninhydrin and 2,4-dinitrophenylhydrazine. Flash column chromatography was carried out on silica gel 60 (particle size 0.040–0.063 mm; Merck, Germany). Melting points were determined on a Reichert hot stage microscope and are uncorrected. 1H NMR spectra were recorded on a Bruker AvanceIII 400 MHz spectrometer at 295 K and 400 MHz, and are reported in ppm using solvent as internal standard (DMSO-d6 at 2.50 ppm, CDCl3 at 7.26 ppm). 13C NMR spectra were recorded on a Bruker Avance III 400 MHz spectrometer at 295 K and 100 MHz, and are reported in ppm using solvent as internal standard (DMSO-d6 at 39.5 ppm). Mass spectra data were recorded using a Q-Tof Premier (Waters-Micromass, Manchester, UK). HPLC analyses were performed on an Agilent Technologies HP 1100 instrument with a G1365B UV-vis detector, a G1316A thermostat, and a G1313A autosampler, using a Phenomenex Luna 5 μM C18 column (4.6 mm×150 mm) at flow rate of 1.0 mL/min. The eluent consisted of 0.1% trifluoroacetic acid in water (A) and methanol (B). Gradient was 20% B to 80% B in 20 min. The purity of the tested compounds was established to be ≥95%. All experimental procedures are described in Information S1.
Protein expression and purification
The gene encoding DdlB from E. coli JM109 was amplified by PCR using the primers DdlBF5′ ACTGATAAAATCGCGGTCCTG 3′ and DdlBR 5′TTAGTCCGCCAGTTCCAGAATTCG′. The resulting product was cloned into pQE-30 UA (Qiagen), sequenced and transformed into E. coli BL21(λDE3). For overexpression, the resulting strain was grown and lysed as described in the pET manual (Novagen). The enzyme was expressed with an N-terminal polyhistidine tag and purified using a nickel affinity resin as described by the manufacturer (Novagen) .
Colorimetric Inhibition Assay
The target compounds were tested for their ability to inhibit the D-Ala-adding activity of DdlB ligase with the colorimetric malachite green method in which orthophosphate generated during the reaction is measured. Each compound was tested in duplicate at 100, 250 or 500 μM in a mixture, final volume 50 μL, containing 50 mM Hepes (pH 8.0), 5 mM MgCl2, 10 mM (NH4)2SO4, 10 mM KCl, 700 μM D-Ala, 500 μM ATP, purified His-tagged DdlB (diluted in 50 mM Hepes (pH 7.2) and 1 mM DTT) and the test compound dissolved in DMSO. The final concentration of DMSO was 5% (v/v). The reaction mixture was incubated at 37°C for 20 min, then quenched with 100 μL of Biomol reagent and absorbance at 650 nm was measured after 5 min. To exclude possible promiscuous inhibitors, all compounds were tested in the presence of Triton-114 (0.005%). Residual activities were calculated relative to control assays without the compounds and with DMSO. IC50 values, the concentrations of the compounds at which the residual activities were 50%, were determined by measuring the residual activities in triplicate at seven different compound concentrations. Ki determinations were performed under similar conditions using D-Ala (10 mM), ATP (50, 100, 200, 300 and 500 μM) and inhibitor (50, 100, 200, 250, 350, 500 μM) with 20 min incubation at 37°C.
Surface plasmon resonance (SPR)
The binding constants were obtained by using a Biacore T100 (Biacore, GE Healthcare, USA). The enzyme was immobilizated on the surface of the CM5 sensor chip in the running buffer without DMSO (50 mM Hepes, 150 mM NaCl, pH 7.4) according to the manufacturer's suggestions. The surface of the CM5 sensor chip was activated with a 7-min injection of the mixture N-hydroxysuccinimide and 1-ethyl-3-(3-dimethylpropyl)-carbodiimide as suggested by the manufacturer. Two 1 min injections of 50 μg/ml DdlB diluted in 10 mM Na-acetate, pH 4.0 were applied on the second flow cell. The first flow cell was left unmodified and served as a control for non-specific binding of tested compounds. The remaining active groups on the surface of both flow cells were deactivated with a 7-min injection of ethanolamine. The level of immobilized enzyme was around 10000 response units.
Each analyte was titrated, with 3 or 4 repetitions, using different concentrations according to their solubility in running buffer (50 mM Hepes, 150 mM NaCl, 5% DMSO, pH 7.4), usually from 0,781 μM to 500 μM. One concentration was repeated at the end of the assay in each dilution series, in order to check the surface stability and repeatability. The association lasted 60 seconds at a flow-rate 30 μl/min. No regeneration was needed. All experiments were performed at 25°C. Sensorgrams were double referenced by subtracting the signal obtained in the empty flow cell and the injection of the buffer. The steady-state response levels were fitted using the Steady State Affinity model in Biacore T100 Evaluation software.
Isothermal titration calorimetry (ITC)
The heat changes upon binding were measured using a VP-ITC microcalorimeter from MicroCal, LLC (Northampton, MA, USA). Purified DdlB stock solution in 20% glycerol was dialysed for 40 hours at 4°C (50 mM Hepes, pH = 8.0, 10 mM KCl, 10 mM (NH4)2SO4, 5 mM MgCl2, and 0.01% Triton X-114) prior to titration. The ligand solutions were prepared by adding a stock solution of 14 or 33 in DMSO to the dialysis buffer to obtain final 50 μM solution of the DdlB inhibitor in 5% DMSO. Successive aliquots (11–31 μl) of the degassed ligand solution were injected at 5–8 min intervals by a motor driven syringe (300 μl) into the degassed DdlB solution (approximately 2 μM, 5% DMSO) in the calorimeter cell (V = 1.386 ml) with constant stirring (300 rpm) at 37°C. At the end of experiment the final ratio of ligand:enzyme in the titration cell was about 6∶1. The titration data was further corrected for the heat changes observed in the control titration of ligand solution into the dialysis buffer, 5% DMSO, alone. The experimental data was analysed using the Origin 7.0 software provided by MicroCal and fitted by a home written program, based on the non-linear Levenberg–Marquardt χ2 regression procedure, assuming a single binding site model (two parameter fit) :where P, L, and PL represent DdlB, ligand, and DdlB-ligand complex, ΔH and are the measured enthalpy upon aliquot addition and the standard enthalpy change of the binding reaction, and represent the total number of moles of ligand and DdlB-ligand complex in the titration cell, r is the bound ligand to total protein concentration,[P]tot, ratio and Kb is the binding constant. A detailed explanation of the applied model equation is given in the Information S2.
Ligand and protein preparation.
Three-dimensional models of the target compounds were built from a standard fragment library, and their geometries optimized using the CHARMm force field  with MMFF94  partial atomic charges. The Smart Minimizer algorithm, as available in Accelrys Discovery Studio 3.0 (DS)  running on a workstation with Intel Core i7 860 CPU processor, 8 GB RAM, two 750 GB hard drives and an Nvidia GT220 GPU graphic card, running Centos 5.5, was used for energy minimization until the gradient value was smaller than 0.001 kcal mol−1 Å−1. Molecular docking calculations were performed using Dock Ligands (CDOCKER) protocol available in DS. Prior to docking, target enzyme DdlB, co-crystallized with ADP and phosphoryl phosphonate-based inhibitor (PDB code: 1IOV ), was prepared using Prepare Protein protocol in DS, during which the protein was typed with CHARMm force field, hydrogen atoms were added, water molecules were deleted and protonation states were assigned. Binding site was defined as a sphere with radius 13.9 Å around the centroid of the ADP molecule (x = 19.504, y = 3.704, z = 36.555), which was large enough to accommodate the ATP and both D-Ala binding sites.
Docking validation and ligand docking.
In order to validate CDOCKER as a suitable docking program for the binding mode prediction of the designed potential DdlB inhibitors, ADP was docked in the defined DdlB active site. A set of 10 starting random conformations was generated from the initial ligand structure through 1000 steps (1 fs/step) of high temperature MD with target temperature set to 1000 K. Electrostatic interactions were included in the random structure generation. For each of the MD-generated ligand conformations, 10 rigid-body rotations about its centre of mass were used as the initial conformations in the vicinity of the binding site. MD simulated annealing (SA) was then used, starting from these initial binding site conformations, to search for low energy conformations of the ligand in the defined binding site. The heating phase of SA consisted of 2000 steps (1 fs/step) of heating from temperature 300 K to 700 K, followed by 5000 steps (1 fs/step) of cooling phase to cool back from 700 K to 300 K. A final minimization of the ligand in the rigid receptor, using full potential energy terms, was performed in CHARMm force field. For each final pose, the CHARMm energy and the interaction energy alone were calculated. The poses were sorted by CHARMm energy and the 100 best top scoring poses were retained. The ten best docking poses were inspected visually and compared to the binding mode of ADP in the crystal structure of the DdlB-ADP complex (PDB code: 1IOV). The best ranked CDOCKER-calculated ADP conformation in the DdlB active site had an all heavy atom RMSD value of only 0.58 Å compared to the experimentally determined conformation of ADP in the DdlB active site.
Target compounds were docked to the DdlB active site using Dock Ligands (CDOCKER) protocol, with the same parameters as for the validation of the docking protocol with the ADP.
Minimum inhibitory concentrations (MICs) were determined by broth microdilution against E. coli 1411, SM1411 (acrAB deficient derivative of 1411) , AB734 and ES100 (tolC deficient derivative of AB734)  according to CLSI guidelines . MICs were repeated for each strain in the presence of polymyxin B nonapeptide (4 μg/ml) to assess the impact of outer-membrane permeability on antimicrobial activity .
Kinetic analysis of DdlB inhibition of 14 (a); Kinetic analysis of DdlB inhibition of 33 (b). Data were fitted for competitive, noncompetitive and uncompetitive inhibition models using SigmaPlot 11.0 software and Ki values for the best fitted model were calculated.
Superposition of E. coli biotin carboxylase (PDB entry: 2V58, in yellow) and E. coli DdlB (PDB entry: 1IOV, in green) crystal structures. Inhibitor 33 from the biotin carboxylase crystal structure is presented in yellow sticks, while its CDOCKER-calculated binding mode in the DdlB active site is shown in grey sticks (a); Schematic representation of interactions between 33 and biotin carboxylase active site residues as generated by PoseViewWeb  (b).
Structurally similar ATP-binding sites to Ddl ATP-binding site as obtained by ProBiS  .
The authors would like to thank Assistant Professor Dr. Bogdan Štefane for his help with the syntheses and Professor Dr. Roger Pain for critical reading of the manuscript.
Conceived and designed the experiments: VS TT AK VH MBR GA JB AO CR AZ. Performed the experiments: VS EA TT AK VH MH CR. Analyzed the data: VS TT AK VH GA AO CR AZ. Contributed reagents/materials/analysis tools: GA JB IC AO. Wrote the paper: VS TT AK VH MBR GA SG AO AZ.
- 1. Silver LL (2007) Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov 6: 41–55.
- 2. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, et al. (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48: 1–12.
- 3. Timothy DHB (1999) 3.10 – Bacterial Peptidoglycan Biosynthesis and its Inhibition. Comprehensive Natural Products Chemistry. Oxford: Pergamon. 241–294.
- 4. Vollmer W, Blanot D, de Pedro MA (2008) Peptidoglycan structure and architecture. FEMS Microbiol Rev 32: 149–167.
- 5. Bugg TDH, Braddick D, Dowson CG, Roper DI (2011) Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 29: 167–173.
- 6. Wong KK, Pompliano DL (1998) Peptidoglycan biosynthesis. Unexploited antibacterial targets within a familiar pathway. Adv Exp Med Biol 456: 197–217.
- 7. Barreteau H, Kovac A, Boniface A, Sova M, Gobec S, et al. (2008) Cytoplasmic steps of peptidoglycan biosynthesis. FEMS Microbiol Rev 32: 168–207.
- 8. Zawadzke LE, Bugg TD, Walsh CT (1991) Existence of two D-alanine:D-alanine ligases in Escherichia coli: cloning and sequencing of the ddlA gene and purification and characterization of the DdlA and DdlB enzymes. Biochemistry 30: 1673–1682.
- 9. Gholizadeh Y, Prevost M, Van Bambeke F, Casadewall B, Tulkens PM, et al. (2001) Sequencing of the ddl gene and modeling of the mutated D-alanine:D-alanine ligase in glycopeptide-dependent strains of Enterococcus faecium. Protein Sci 10: 836–844.
- 10. Tytgat I, Colacino E, Tulkens PM, Poupaert JH, Prévost M, et al. (2009) DD-ligases as a potential target for antibiotics: past, present and future. Curr Med Chem 16: 2566–2580.
- 11. Neuhaus FC (1962) The enzymatic synthesis of D-alanyl-D-alanine. I. Purification and properties of D-alanyl-D-alanine synthetase. J Biol Chem 237: 778–786.
- 12. Bugg TD, Dutka-Malen S, Arthur M, Courvalin P, Walsh CT (1991) Identification of vancomycin resistance protein VanA as a D-alanine:D-alanine ligase of altered substrate specificity. Biochemistry 30: 2017–2021.
- 13. Fan C, Park IS, Walsh CT, Knox JR (1997) D-alanine:D-alanine ligase: phosphonate and phosphinate intermediates with wild type and the Y216F mutant. Biochemistry 36: 2531–2538.
- 14. Galperin MY, Koonin EV (1997) A diverse superfamily of enzymes with ATP-dependent carboxylate-amine/thiol ligase activity. Protein Sci 6: 2639–2643.
- 15. Healy VL, Mullins LS, Li X, Hall SE, Raushel FM, et al. (2000) D-Ala-D-X ligases: evaluation of D-alanyl phosphate intermediate by MIX, PIX and rapid quench studies. Chem Biol 7: 505–514.
- 16. Mullins LS, Zawadzke LE, Walsh CT, Raushel FM (1990) Kinetic evidence for the formation of D-alanyl phosphate in the mechanism of D-alanyl-D-alanine ligase. J Biol Chem 265: 8993–8998.
- 17. Neuhaus FC, Lynch JL (1962) Studies on the inhibition of D-alanyl-D-alanine synthetase by the antibiotic D-cycloserine. Biochem Biophys Res Commun 8: 377–382.
- 18. Lu P-L, Peng C-F, Hwang J-J, Chen Y-H (2008) Activity of twelve second-line antimicrobial agents against Mycobacterium tuberculosis in Taiwan. J Chemother 20: 202–207.
- 19. Neuhaus FC, Hammes WP (1981) Inhibition of cell wall biosynthesis by analogues and alanine. Pharmacol Ther 14: 265–319.
- 20. Besong GE, Bostock JM, Stubbings W, Chopra I, Roper DI, et al. (2005) A de novo designed inhibitor of D-Ala-D-Ala ligase from E. coli. Angew Chem Int Ed Engl 44: 6403–6406.
- 21. Sova M, Cadez G, Turk S, Majce V, Polanc S, et al. (2009) Design and synthesis of new hydroxyethylamines as inhibitors of D-alanyl-D-lactate ligase (VanA) and D-alanyl-D-alanine ligase (DdlB). Bioorg Med Chem Lett 19: 1376–1379.
- 22. Kovac A, Majce V, Lenarsic R, Bombek S, Bostock JM, et al. (2007) Diazenedicarboxamides as inhibitors of D-alanine-D-alanine ligase (Ddl). Bioorg Med Chem Lett 17: 2047–2054.
- 23. Wu D, Kong Y, Han C, Chen J, Hu L, et al. (2008) D-Alanine:D-alanine ligase as a new target for the flavonoids quercetin and apigenin. Int J Antimicrob Agents 32: 421–426.
- 24. Triola G, Wetzel S, Ellinger B, Koch MA, Hübel K, et al. (2009) ATP competitive inhibitors of D-alanine-D-alanine ligase based on protein kinase inhibitor scaffolds. Bioorg Med Chem 17: 1079–1087.
- 25. Kovac A, Konc J, Vehar B, Bostock JM, Chopra I, et al. (2008) Discovery of new inhibitors of D-alanine:D-alanine ligase by structure-based virtual screening. J Med Chem 51: 7442–7448.
- 26. Vehar B, Hrast M, Kovač A, Konc J, Mariner K, et al. (2011) Ellipticines and 9-acridinylamines as inhibitors of D-alanine:D-alanine ligase. Bioorg Med Chem 19: 5137–5146.
- 27. Škedelj V, Tomašić T, Mašič LP, Zega A (2011) ATP-binding site of bacterial enzymes as a target for antibacterial drug design. J Med Chem 54: 915–929.
- 28. Fawaz MV, Topper ME, Firestine SM (2011) The ATP-grasp enzymes. Bioorg Chem 39: 185–191 doi:10.1016/j.bioorg.2011.08.004.
- 29. Miller JR, Dunham S, Mochalkin I, Banotai C, Bowman M, et al. (2009) A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA 106: 1737–1742.
- 30. Huber W (1943) 2,4-Diamino-5-(4-methyl-5-β-hydroxyethylthiazolium chloride)-methylpyrimidine Hydrochloride, a New Analog of Thiamin. J Am Chem Soc 65: 2222–2226.
- 31. Bag S, Tawari NR, Degani MS, Queener SF (2010) Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens. Bioorganic & Medicinal Chemistry 18: 3187–3197.
- 32. Hamby JM, Connolly CJ, Schroeder MC, Winters RT, Showalter HD, et al. (1997) Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem 40: 2296–2303.
- 33. Papahatjis DP, Nikas SP, Kourouli T, Chari R, Xu W, et al. (2003) Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1’. J Med Chem 46: 3221–3229.
- 34. Sakamoto J, Schlüter AD (2007) Shape-Persistent Macrocycles: A Synthetic Strategy that Combines Easy and Site-Specific Decorations with Improved Cyclization Efficiency. European Journal of Organic Chemistry 2007: 2700–2712.
- 35. van den Hoogenband A, Lange JHM, Iwema-Bakker WI, den Hartog JAJ, van Schaik J, et al. (2006) An efficient one-pot synthesis of novel 4-aryl-1-methyloxindoles. Tetrahedron Letters 47: 4361–4364.
- 36. Lanzetta PA, Alvarez LJ, Reinach PS, Candia OA (1979) An improved assay for nanomole amounts of inorganic phosphate. Anal Biochem 100: 95–97.
- 37. O’Neill AJ, Bostock JM, Moita AM, Chopra I (2002) Antimicrobial activity and mechanisms of resistance to cephalosporin P1, an antibiotic related to fusidic acid. J Antimicrob Chemother 50: 839–848.
- 38. Shapiro E, Baneyx F (2002) Stress-based identification and classification of antibacterial agents: second-generation Escherichia coli reporter strains and optimization of detection. Antimicrob Agents Chemother 46: 2490–2497.
- 39. Dixon RA, Chopra I (1986) Leakage of periplasmic proteins from Escherichia coli mediated by polymyxin B nonapeptide. Antimicrob Agents Chemother 29: 781–788.
- 40. Press WH, Flannery BP, Teukolsky SA, Vetterling WT. Numerical Recipes. Oxford, 650–694: Cambridge University Press; 1992.
- 41. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. Journal of Computational Chemistry 4: 187–217.
- 42. Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. Journal of Computational Chemistry 17: 490–519.
- 43. Accelrys Discovery Studio 3.0 is available from Accelrys Inc., San Diego, CA 92121, U.S.
- 44. National Commitee for Clinical Laboratory Standards (NCCLS) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed., vol. 17, No. 2. Approved standard M7-A4: 1997.
- 45. Stierand K, Maass PC, Rarey M (2006) Molecular complexes at a glance: automated generation of two-dimensional complex diagrams. Bioinformatics 22: 1710–1716.
- 46. Konc J, Janezic D (2010) ProBiS algorithm for detection of structurally similar protein binding sites by local structural alignment. Bioinformatics 26: 1160–1168.